Stereotactic Radiotherapy Plus Temozolomide for Refractory Brain Metastases

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Brain Metastases
Interventions
RADIATION

Fractionated Stereotactic Radiotherapy

The regular fraction modes were as follows: a. lesions≥3 cm:52Gy/4Gy/13f or 52.5Gy/3.5Gy/15f; b. lesions\<2cm:36Gy/12Gy/3f or 24Gy/24Gy/1f; for lesions located in function areas, it would be adjusted to 40Gy/8Gy/5f; c. lesions 2-3cm:40-48Gy/8-10Gy/6-4f; d. lesions located in brainstem:50-60Gy/2.5-3Gy/20f.

DRUG

Temozolomide

concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/m2\*5d, q28d, 6cycles

Trial Locations (1)

100021

Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
collaborator

Cancer Foundation, China

OTHER

lead

Chinese Academy of Medical Sciences

OTHER

NCT02654106 - Stereotactic Radiotherapy Plus Temozolomide for Refractory Brain Metastases | Biotech Hunter | Biotech Hunter